GlassScriptPhysician profile
Brandon Lynn Hill
NPI 1801155015
$2,869.20
in general payments reported to CMS, 2019-2025
25 companies · $906 in 2025
The $906 reported for 2025 was more than what 83% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.55 · 2022: $345 · 2023: $543 · 2024: $998 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,124.82 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $309.87 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $179.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $155.55 | 2022-2025 | |
| Dexcom, INC. | $137.88 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.42 | 2022-2024 | Ofev, Jardiance |
| Pfizer INC. | $116.58 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $101.27 | 2023-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $67.79 | 2021-2025 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $67.65 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.49 | 2024-2025 | Rejoyn |
| Amgen INC. | $57.46 | 2023-2024 | Repatha, Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $46.34 | 2022 | |
| Corcept Therapeutics | $45.19 | 2025 | Korlym |
| Lilly USA, LLC | $42.69 | 2023-2024 | Mounjaro, Jardiance, Emgality |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42.68 | 2022-2023 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $38.42 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Mylan Specialty L.P. | $23.14 | 2024 | Yupelri |
| Pulmonx Corporation | $22.12 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Phathom Pharmaceuticals, INC. | $21.39 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $17.58 | 2025 | Auvelity |
| Astellas Pharma US INC | $16.04 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $16.01 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.86 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.